A detailed history of Blueprint Investment Partners LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Blueprint Investment Partners LLC holds 4,917 shares of LLY stock, worth $3.58 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares
4,917
Previous 4,692 4.8%
Holding current value
$3.58 Million
Previous $4.25 Million 2.54%
% of portfolio
0.95%
Previous 1.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$772.14 - $960.02 $173,731 - $216,004
225 Added 4.8%
4,917 $4.36 Million
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $1.18 Million - $1.48 Million
1,628 Added 53.13%
4,692 $4.25 Million
Q1 2024

May 13, 2024

SELL
$592.2 - $792.28 $83,500 - $111,711
-141 Reduced 4.4%
3,064 $2.38 Million
Q4 2023

Feb 13, 2024

BUY
$525.19 - $619.13 $401,245 - $473,015
764 Added 31.3%
3,205 $1.87 Million
Q3 2023

Nov 15, 2023

BUY
$434.7 - $599.3 $175,184 - $241,517
403 Added 19.77%
2,441 $1.31 Million
Q2 2023

Aug 15, 2023

SELL
$350.74 - $468.98 $62,431 - $83,478
-178 Reduced 8.03%
2,038 $955,000
Q1 2023

May 12, 2023

SELL
$310.63 - $364.82 $1.31 Million - $1.54 Million
-4,233 Reduced 65.64%
2,216 $761,000
Q4 2022

Feb 14, 2023

BUY
$321.55 - $374.67 $146,948 - $171,224
457 Added 7.63%
6,449 $2.36 Million
Q3 2022

Nov 09, 2022

BUY
$296.48 - $337.87 $744,757 - $848,729
2,512 Added 72.18%
5,992 $1.94 Million
Q2 2022

Aug 09, 2022

BUY
$278.73 - $327.27 $514,814 - $604,467
1,847 Added 113.1%
3,480 $1.13 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $56,560 - $70,290
-241 Reduced 12.86%
1,633 $468,000
Q4 2021

Feb 15, 2022

BUY
$224.85 - $279.04 $162,566 - $201,745
723 Added 62.81%
1,874 $517,000
Q3 2021

Nov 04, 2021

BUY
$221.6 - $272.71 $255,061 - $313,889
1,151 New
1,151 $266,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $691B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Blueprint Investment Partners LLC Portfolio

Follow Blueprint Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueprint Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueprint Investment Partners LLC with notifications on news.